Skip to Main Content
Bora Pharmaceuticals Completes the Acquisition of Upsher-Smith

Company News

MHLW Approves New Indication for OLANZAPINE Formulation and New Administration for MEROPENEM Formulation

Osaka, Japan –April 4, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of two partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for OLANZAPINE Tablets 2.5mg “SAWAI”, 5mg “SAWAI”, 10mg “SAWAI” and Fine Granules 1% “SAWAI” ...
Read More

Announcement on Sawai Organizational and Personnel Changes

Osaka, Japan –March 26, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the following organizational and personnel changes, effective April 1, 2018. OrganizationalChanges “Development QA” is renamed “QA Department”. ※The ...
Read More

Join Our Team!

We’re hiring

Search Our Jobs